SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJames Halstead Regulatory News (JHD)

Share Price Information for James Halstead (JHD)

Share Price is delayed by 15 minutes
Get Live Data
128.80    4.60 (3.70%)
Bid:
128.20
Ask:
129.60
Spread: 1.40 (1.092%)
Market Cap: £536.34m
JHD Live PriceLast checked at - London Stock Exchange

Intraday James Halstead Share Chart

Pre-Close Trading Statement

30 Jul 2019 07:00

RNS Number : 1051H
James Halstead PLC
30 July 2019
 

 

 

 

30 July 2019

 

Pre-Close Trading Statement

 

 

James Halstead plc, the commercial flooring manufacturer and distributor, is providing the following trading update ahead of its final results for the year ended 30 June 2019.

 

We are pleased to report that sales for the year were ahead of the comparative year and at a record level. This, we feel, represents a creditable performance in still difficult trading conditions. Flooring installations through the year were wide ranging such as Harrow School, Euro Disney's Hotel New York and Chanel concessions across the globe and the Al Thumama Stadium in Qatar. Our healthcare business continues to make good progress and projects completed included Poissy Hospital in France and the newly built Quillota Hospital in Chile. It is particularly pleasing to report that our UK turnover (representing about 35% of total sales) is ahead of the prior year, by some 7%, in a market that seems to be quite robust despite the well reported high street retailer issues.

 

Across many regions, but especially in Europe competition is ever increasing with new entrants peddling an increasing array of flooring of various degrees of quality and availability. In the German market we have maintained market share but turnover was at a lower level. There are markets with double digit growth and France, South America and Holland are examples. We remain confident that our investment in marketing, sampling, sales representation and training / technical support continue to differentiate us from the pack.

 

Raw material prices are stable and the availability problems of last year have ameliorated and working capital remains robustly managed with our cash generation secure. Our long term focus on delivery of shareholder returns is undiminished.

 

Our profit for the year has grown and will be at a record level, representing modest growth.

 

 

 

 

 

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. 

 

 

Enquiries:

 

James Halstead plc

Telephone: 0161 767 2500

Mark Halstead, Chief Executive

Gordon Oliver, Finance Director

Hudson Sandler

Telephone: 020 7796 4133

Nick Lyon

Nick Moore

Panmure Gordon (Nominated advisor and broker)

Telephone: 020 7886 2500

Ben Thorne

Dominic Morley

Arden Partners (Broker)

Telephone: 020 7614 5900

Tom Price

Matthew Groves

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTDKLFLKDFFBBE
Date   Source Headline
1st Dec 20177:00 amRNSAGM Statement
20th Oct 20173:00 pmRNSAnnual Report & Accounts
2nd Oct 20177:00 amRNSBoard Changes
2nd Oct 20177:00 amRNSPRELIMINARY ANNOUNCEMENT OF AUDITED RESULTS
14th Sep 201712:42 pmRNSNotice of Preliminary Results
14th Sep 20177:00 amRNSNotice of Preliminary Results
1st Aug 201710:43 amRNSTotal Voting Rights
1st Aug 20177:00 amRNSPre-Close Trading Statement
31st Jul 20175:53 pmRNSDirector/PDMR Shareholding
3rd Jul 20175:40 pmRNSTotal Voting Rights
3rd Jul 20175:37 pmRNSBlock listing Interim Review
23rd Jun 20174:12 pmRNSDirector/PDMR Shareholding
12th Jun 201712:54 pmRNSDirector/PDMR Shareholding
9th Jun 20175:37 pmRNSTotal Voting Rights
12th May 20175:29 pmRNSDirector/PDMR Shareholding
12th May 20173:59 pmRNSDirector/PDMR Shareholding
5th Apr 20172:36 pmRNSDirector/PDMR Shareholding
29th Mar 20177:00 amRNSInterim Results
6th Mar 20177:00 amRNSNotice of Results
30th Jan 20177:00 amRNSPre Close Trading Statement
13th Dec 201611:13 amRNSResult of AGM
2nd Dec 20167:00 amRNSAGM Statement
1st Dec 20167:00 amRNSTotal Voting Rights
1st Nov 201612:24 pmRNSTotal Voting Rights
21st Oct 20167:00 amRNSAnnual Financial Report
3rd Oct 20167:00 amRNSPRELIMINARY ANNOUNCEMENT OF AUDITED RESULTS
21st Sep 20167:00 amRNSNotice of Preliminary Results
15th Aug 20167:00 amRNSAdoption of Financial Reporting Standard (FRS) 101
1st Aug 20167:00 amRNSPre-Close Trading Statement
1st Jul 20163:41 pmRNSBlock listing Interim Review
31st Mar 20167:00 amRNSInterim Results
8th Mar 20167:00 amRNSNotice of Interim Results
1st Feb 20164:51 pmRNSTotal Voting Rights
1st Feb 20167:00 amRNSPre Close Trading Statement
3rd Dec 20155:20 pmRNSDirector/PDMR Shareholding
1st Dec 20152:45 pmRNSTotal Voting Rights
27th Nov 201512:00 pmRNSChairman's Statement to the Annual General Meeting
2nd Nov 201511:39 amRNSTotal Voting Rights
29th Oct 20154:44 pmRNSDirector/PDMR Shareholding
23rd Oct 20159:45 amRNSAnnual Financial Report & Notice of AGM
29th Sep 20157:00 amRNSFinal Results
18th Sep 20157:00 amRNSNotice of Preliminary Results
31st Jul 20157:00 amRNSTotal Voting Rights
29th Jul 20157:00 amRNSPre-Close Trading Statement
28th Jul 20156:00 pmRNSBlocklisting Interim Review
24th Jul 20155:00 pmRNSDirector/PDMR Shareholding
1st Jul 20157:00 amRNSChange of Adviser
3rd Jun 20157:00 amRNSTotal Voting Rights
31st Mar 20157:00 amRNSInterim Results
20th Mar 20154:31 pmRNSNotice of Results - Replacement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.